Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

ines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the further development of MAP0005 and the potential application of MAP Pharmaceuticals' technologies to additional product candidates. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and commercialization of product candidates incorporating MAP Pharmaceuticals' technologies. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10K, filed with the SEC on March 20, 2008, available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Japan Pharma Outlook 2015: Year to Watch out for ... report to their offering. The new ... from April -2014 (Annexure 1) is a game changer ... generic or innovator. The most of the companies are ...
(Date:3/5/2015)... and HAMPTON, N.J. , March ... MNK ), a leading global specialty biopharmaceutical ... announced today that they have entered into a definitive ... Ikaria, Inc. from a Madison Dearborn -led investor ... Subject to customary closing conditions, the ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Global Rising Stars Outlook 2015" report to ... diseases are being sought after with fresh vigor as ... field which is poised to bring a paradigm change ... decades is the Stem cell therapy/Regenerative Medicine space. ...
Breaking Medicine Technology:Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2
... UK -- LONDON, November 16, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... NASHVILLE, Tenn., Nov. 15, 2010 Pathfinder Therapeutics, ... the value of Explorer™, its image-guided surgical platform, ... sites participating in the study include: Memorial Sloan-Kettering ... Portland Medical Center, and UNC-Chapel Hill. ...
Cached Medicine Technology:Cable&Wireless Worldwide Extends Partnership With Boots UK 2Cable&Wireless Worldwide Extends Partnership With Boots UK 3Cable&Wireless Worldwide Extends Partnership With Boots UK 4Cable&Wireless Worldwide Extends Partnership With Boots UK 5Cable&Wireless Worldwide Extends Partnership With Boots UK 6Cable&Wireless Worldwide Extends Partnership With Boots UK 7Cable&Wireless Worldwide Extends Partnership With Boots UK 8Pathfinder Initiates Minimally Invasive Surgical Navigation Study 2
(Date:3/6/2015)... Nolen, the largest family-owned pest control company in America, ... first independently-owned and operated franchise in North Carolina, serving ... Rock Hill, SC area. The ribbon cutting ceremony was ... , The Truly Nolen Carolina team has ... control industry. Locally owned and operated by local Charlotteans, ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 You ... company, created a unique ‘energy’ experiment to determine ... , After quick ‘5 -7 minute’ ... than 150+ countries reported their life improving - ... reported positive results. , According to research, respondents ...
(Date:3/6/2015)... Fluid Running® Owner, Jennifer Conroyd, an ... Fluid Running® method 3 years ago when ... She hit upon the trifecta of combining matched-bpm music, ... maximum-resistance, deep water running technique. She not only completed ... running workout that made the experience both enjoyable and ...
(Date:3/5/2015)... London, UK (PRWEB) March 06, 2015 ... of them being first–in-class. AstraZeneca tops the list scoring ... field obtained over 25% of all FDA approved drug ... total. First-in-class mechanisms such as anti-PCSK9, anti-PD1 and CDK ... have been approved by the FDA to treat metastatic ...
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , a ... repair market, reported record revenue of $4.79 million for ... $2.98 million in the year-ago fourth quarter demonstrating the ... “Our strong fourth quarter revenue growth reflects the market’s ... is driving increased surgeon adoption of our unique product ...
Breaking Medicine News(10 mins):Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... and start over after they,ve been denied disability benefits; Allsup explains the ... ... 31, 2008 -- Getting a denial letter after hours of work and ... call it quits, according to Allsup , which represents people nationwide ...
... such study ever published finds that, while about 40 ... 12 percent indicate that those issues are a source ... a Massachusetts General Hospital (MGH) physician appears in the ... , "Sexual problems are common in women, but problems ...
... Attributes Innovation to its 385 Percent Revenue Growth, ... Health Market Science,Inc. has been named to Deloitte,s ... of the 50 fastest growing technology, media,telecommunications and ... LLP,one of the nation,s leading professional services organizations. ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), a leading provider ... present at November,investment conferences hosted by Oppenheimer & Co., Credit ... from:, -- 1:20 p.m. to 1:55 p.m. ... & Co. 19th Annual Healthcare Conference in ...
... researchers say , , THURSDAY, Oct. 30 (HealthDay News) -- ... years, but heavy metal contamination found in some European ... into a hazard, British researchers report. , Heavy metals ... disease and may also increase oxidative stress, which can ...
... for a four-star ease of use ... rear and front facing positions!, OAK BROOK, Ill., Oct. ... RC2 Corporation (Nasdaq: RCRC ),( http://www.learningcurve.com ), was recently ... First Years True,Fit C630 Convertible Car Seat a four-star Ease ...
Cached Medicine News:Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 2Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 3Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 4Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 5Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 6Health News:While prevalent, sexual problems in women not always associated with distress 2Health News:Health Market Science, Inc. Ranked Number 17 in Deloitte's Fast 50 Program for Greater Philadelphia 2Health News:Health Market Science, Inc. Ranked Number 17 in Deloitte's Fast 50 Program for Greater Philadelphia 3Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 2Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 3Health News:Heavy Metals Can Taint Wine 2Health News:Heavy Metals Can Taint Wine 3Health News:The First Years True Fit C630 Convertible Car Seat Recieves Highest Given Rating From the National Highway Traffic Safety Administration 2
Curved shafts with delicate 1 x 2 teeth. Serrated handle. Polished finish....
Inner jaw space 2.0 mm - 45 degree tip angulation. 20 gauge (.89 mm) diameter shaft and stationary distal jaw. Lightweight squeeze handle with dull finish. Jaws 1.5 mm serrated....
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with heavy 1 x 2 teeth. Non-magnetic with serrated handle and polished finish....
Medicine Products: